"All in" for a huge pot: The PROWESS-SHOCK trial for refractory septic shock

Surgical Infections

Volumn 8, Issue 5, 2007, Pages 491-493

  Barie, Philip S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN; PLACEBO;

APACHE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; MEDICAL ETHICS; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZATION; SEPSIS; SEPTIC SHOCK; SURGICAL PATIENT; TREATMENT OUTCOME;

ANTI-INFECTIVE AGENTS; HUMANS; PROTEIN C; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; SHOCK, SEPTIC;

EID: 36148954321     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2007.9980     Document Type: Editorial

References (11)

1. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
2. Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005;353:1332-1341.
3. Nadel S, Goldstein B, Williams MD, et al. Drotrecogin alfa (activated) in children with severe sepsis: A multicentre phase III randomised controlled trial. Lancet 2007;369:836-843.
4. Payen D, Sablotzki A, Barie PS, et al. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: Analysis of efficacy and safety data in a large surgical cohort. Surgery 2007;141:548-561.
5. Barie PS, Williams MD, McCollam JS, et al. PROWESS Surgical Evaluation Committee. Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis. Am J Surg 2004;188:212-220.
6. Barie PS. An opinion too far - the campaign against the Surviving Sepsis Campaign. Surg Infect 2006;7:485-488.
7. Friedrich JO. Drotrecogin alfa (activated) in severe sepsis. [comment]. N Engl J Med 2006; 354:94-96.
8. Opal SM. Can we RESOLVE the treatment of sepsis? [comment]. Lancet 2007;369:803-804, 2007.
9. Gardlund B. Activated protein C (Xigris) treatment in sepsis: A drug in trouble. Acta Anaesthesiol Scand 2006;50:907-10.
10. Martí-Carvajal A, Salanti G, Cardona AF. Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev 2007;3: CD004388.
11. U. S. Food and Drug Administration. Xigris Face-to-Face Meeting, March 14, 2007. IND 5919, Amendment 460.